J

Johnson & Johnson

Global healthcare company offering pharma, devices.

Healthcare Solutions Operations Lead

Full-TimePosted on 9/28/2026Deadline 10/19/26
€78.3k - €135.7k/yr+ Annual bonus + Sales commissions
Expert
Leipzig, Germany+8 moreMore locations: Dortmund, Germany | Aachen, Germany | Cologne, Germany | Hamburg, Germany | Frankfurt, Germany | Stuttgart, Germany | Berlin, Germany | Munich, Germany
Remote

About the job

Requirements
  • Significant experience leading event operations, professional education operations, or a comparable service-delivery function in a complex, regulated environment.
  • Proven leadership capability, including setting direction and expectations, coaching and developing teams, managing performance, allocating resources effectively, and building a culture of accountability and continuous improvement.
  • Demonstrated success in streamlining and standardising processes to support growth, improve service levels, and deliver measurable efficiency gains.
  • Strong judgement and composure when managing competing priorities, urgent issues, and last-minute requests across multiple countries and stakeholders.
  • Strong understanding of compliance, governance, documentation, and audit-ready execution, with the ability to embed requirements into practical operational processes.
  • Experience overseeing HCP contracting processes and working with Legal, Compliance, Procurement, and business stakeholders to improve governance, efficiency, transparency, and turnaround times.
  • Experience managing budgets, supplier performance, and delivery trade-offs within defined financial constraints.
  • Experience using event-management and workflow platforms to improve scalability, visibility, and data quality.
  • Fluency in English is required.
Responsibilities
  • Provide clear and visible leadership for the operations department, setting strategic direction, performance expectations, and a culture of accountability, collaboration, responsiveness, and continuous improvement; coach and develop team members to strengthen capability, engagement, and succession.
  • Set priorities, allocate workload, and flex team capacity to deliver planned activities while responding effectively to urgent and last-minute requests.
  • Streamline and standardise end-to-end event operations through clear processes, service standards, templates, workflows, escalation pathways, and decision rights.
  • Establish scalable planning, intake, and prioritisation processes that provide visibility of demand, capacity, timelines, risks, and delivery status.
  • Ensure events and related operational activities are delivered consistently, efficiently, and in accordance with internal compliance, governance, documentation, and audit-readiness requirements.
  • Lead the management and continuous improvement of the end-to-end HCP contracting process, establishing clear ownership, standard workflows, service expectations, and performance measures to improve quality, compliance, transparency, and turnaround times.
  • Own budget oversight for the department, monitor event-related spend and supplier invoices, and make resource and delivery decisions within agreed financial limits.
  • Act as the senior escalation point for operational issues, resolving time-critical challenges with practical solutions while protecting compliance, quality, and budget.
  • Define and monitor service levels, operational KPIs, and dashboards to measure efficiency, workload, quality, compliance, and scalability.
  • Lead continuous improvement initiatives, identify bottlenecks, and remove unnecessary complexity to increase speed, consistency, and team capacity.
  • Drive effective adoption of operational systems, including CVENT and Veeva Vault, to enable standardised workflows, reliable data, and efficient execution.
  • Manage and develop strategic supplier relationships, ensuring service quality, responsiveness, value for money, and adherence to agreed processes.
  • Partner closely with Professional Education Managers, Healthcare Solutions leadership, Physician Program Directors, Regional Program Managers, Finance, Procurement, Legal, Compliance, Marketing, Regulatory, and external providers to align plans and resolve delivery constraints.
  • Provide leadership with clear operational updates, capacity forecasts, budget visibility, risk assessments, and recommendations for scaling the function.
  • Manage the operational specialists responsible for contracting, grants and procurement administration; Healthcare Solutions project coordination and internal communication; Professional Education participant management, logistics, AMEX booking coordination, COLADA administration and course or roundtable support; CVENT event-management implementation and adoption; and Veeva Vault copy-approval process coordination and governance.
Desired Qualifications
  • German language skills are beneficial.
  • CVENT, COLADA, or Veeva Vault experience is advantageous.

About the company

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
  • TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
  • CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.

What critics are saying

  • Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
  • Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
  • AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.

What makes Johnson & Johnson unique

  • J&J has 28 billion-dollar products, reducing dependence on any single franchise.
  • TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
  • CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -2%

2 year growth

↓ -1%
Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.